Alzheimer’s disease (AD) is a form of dementia that impairs memory, thought, language, and behavior. The progression of Alzheimer’s disease is accelerated by increasing age and the high number of people suffering from the disease who are 65 and above. It starts with little symptoms and progresses to serious brain damage, where people lose their capacity to converse and respond to their surroundings. According to the Alzheimer’s Association, more than 5.5 million Americans have Alzheimer’s dementia in 2017. Alzheimer’s disease affects around 5.3 million people of age 65 and above, and around 200,000 people below the age of 65. Non-drug treatments and symptomatic drugs can be used to treat Alzheimer’s behavioral and cognitive symptoms. Moreover, there is no specific treatment for Alzheimer’s disease on the market, which offers the opportunity to the development of Anti- β- Alzheimer therapies
Request Here For FREE PDF Brochure
Global Anti-β-Alzheimer Therapies Market Taxonomy:
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
A breakthrough therapy is expected to drive significant growth of the global anti-Alzheimer therapies market.
Biogen Pharmaceuticals released data from a pre-specified annual assessment of PRIME, a Phase 1b placebo-controlled trial of aducanumab in individuals with prodromal or moderate Alzheimer’s disease, in July 2015. Phase I clinical trials on 166 individuals showed substantial success in terms of lowering Amyloid beta levels in the brain and a slowing of cognitive function when compared to a placebo-controlled treatment group. In U.S. Food and Drug Administration (FDA)-approved specialized memory tests, the Phase III efficacy trial revealed significant cognitive results. In 2016, Eli Lilly and Company, announced the development of the Alzheimer’s drug solanezumab, that was still in phase III clinical trials due to its delayed Alzheimer’s disease progression and high price.
Pfizer Inc. and Johnson & Johnson stated in 2012 that they would stop producing bapineuzumab, an intravenous (IV) Alzheimer’s drug, after the drug failed to benefit patients with memory loss in a second high-profile clinical trial. Such factors restrict a market’s expected growth.
The global anti-β-Alzheimer therapies market is predicted to expand due to the rising prevalence and incidence of Alzheimer’s disease.
Growing elderly population, as well as the issues that come with it, such as dementia, is the primary driver of the global Anti-β-Alzheimer therapies market. According to the Centers for Disease Control and Prevention (CDC), five million people in U.S. suffered from Alzheimer’s disease in 2013, with the number projected to increase to 14 million by 2050. Furthermore, the World Health Organization (WHO) estimates that 47 million individuals worldwide suffer from dementia, with nearly 10 million new cases diagnosed each year.
Dementia was the second highest cause of mortality in Australia in 2013, according to the Australian Bureau of Statistics (ABS). According to the Australian Institute of Health and Welfare (AIHW), the number of persons living with dementia is predicted to increase to around 400,000 by 2020 and 900,000 by 2050. The National Health and Medical Research Council (NHMRC) and the Australian Research Council (ARC) are collaborating to prioritize and support new dementia research initiatives, as well as translate research to enhance dementia care, diagnosis, prevention, and treatment.
Biogen Pharmaceuticals is a major player in the global Anti-β-Alzheimer therapies market.
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Anti-β-Alzheimer Therapies Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Anti-β-Alzheimer Therapies Industry Impact
Chapter 2 Global Anti-β-Alzheimer Therapies Competition by Types, Applications, and Top Regions and Countries
2.1 Global Anti-β-Alzheimer Therapies (Volume and Value) by Type
2.3 Global Anti-β-Alzheimer Therapies (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Anti-β-Alzheimer Therapies Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Anti-β-Alzheimer Therapies Market Analysis
Chapter 6 East Asia Anti-β-Alzheimer Therapies Market Analysis
Chapter 7 Europe Anti-β-Alzheimer Therapies Market Analysis
Chapter 8 South Asia Anti-β-Alzheimer Therapies Market Analysis
Chapter 9 Southeast Asia Anti-β-Alzheimer Therapies Market Analysis
Chapter 10 Middle East Anti-β-Alzheimer Therapies Market Analysis
Chapter 11 Africa Anti-β-Alzheimer Therapies Market Analysis
Chapter 12 Oceania Anti-β-Alzheimer Therapies Market Analysis
Chapter 13 South America Anti-β-Alzheimer Therapies Market Analysis
Chapter 14 Company Profiles and Key Figures in Anti-β-Alzheimer Therapies Business
Chapter 15 Global Anti-β-Alzheimer Therapies Market Forecast (2021-2027)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027